Sia Daneshmand, MD, joins the show to review 2 studies on
the use of erdafitinib for the treatment of non-muscle invasive bladder cancer,
including the THOR-2 trial investigating erdafitinib versus intravesical
chemotherapy in patients who received BCG therapy and recurred with high-risk
NMIBC. Dr. Daneshmand is the director of urologic oncology at the Keck School
of Medicine, University of Southern California, Los Angeles.
